Currently, there are 27.52M common shares owned by the public and among those 26.76M shares have been available to trade.
The company’s stock has a 5-day price change of -4.92% and 62.62% over the past three months. ITRM shares are trading -11.68% year to date (YTD), with the 12-month market performance up to 7.41% higher. It has a 12-month low price of $0.81 and touched a high of $3.02 over the same period. ITRM has an average intraday trading volume of 2.84 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.22%, 4.79%, and 23.86% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Iterum Therapeutics Plc (NASDAQ: ITRM) shares accounts for 6.16% of the company’s 27.52M shares outstanding.
It has a market capitalization of $47.88M and a beta (3y monthly) value of 2.32. The earnings-per-share (ttm) stands at -$2.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.10% over the week and 12.32% over the month.
Analysts forecast that Iterum Therapeutics Plc (ITRM) will achieve an EPS of -0.24 for the current quarter, -0.23 for the next quarter and -0.82 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.24 while analysts give the company a high EPS estimate of -0.24. Comparatively, EPS for the current quarter was -0.81 a year ago. Earnings per share for the fiscal year are expected to increase by 65.98%, and 44.35% over the next financial year.
H.C. Wainwright coverage for the Iterum Therapeutics Plc (ITRM) stock in a research note released on March 15, 2021 offered a Buy rating with a price target of $2.50. SVB Leerink on their part issued Mkt Perform rating on December 11, 2019.
